Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β2-agonists. It has been reimbursed in Portugal as an add-on therapy since May 2019. In order of this, there is crucial need in Portugal to provide key real-word evidence on benralizumab therapy.

This is a real-world retrospective, multicentric, observational study, utilizing secondary data collection from medical records of adults patients (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenotype, who, at the discretion of the physician, received benralizumab accordingly to the clinical practice, in the period after the marketing authorization of benralizumab.

Inclusion Criteria:

• Adults patients with severe asthma treated with benralizumab, who had their first benralizumab dose between July 2019 and October 2020

  • Patients who have at least 1 benralizumab injection and with at least 3 months follow-up data from the first injection.
  • Give voluntary signed informed consent

Exclusion Criteria:

• Currently receiving benralizumab or any other biologic drug for the treatment of asthma in a clinical trial

Severe eosinophilic asthma patients aged 18 and above, treated with benralizumab and who have had their first benralizumab dose between July 2019 and October 2020 and who have at least 1 benralizumab injection and with at least 3 months follow-up data from the first injection.

No IPD is planned to be shared.